Du är här

2016-02-11

Nexstim Oyj: Publishing of Nexstim Plc 2015 Full Year Results

Helsinki, 11 February 2016 at 9:00 a.m.

Nexstim Plc (NXTMH:HEX, NXTMS:STO), a medical technology company aiming to
improve rehabilitation for stroke patients through the use of non-invasive
brain stimulation, will announce its full year results for the year ended 31
December 2015 in the afternoon of Monday 29 February 2016.

A conference call for analysts, investors and media will take place at 16:00
EET on Monday 29 February 2016, hosted by Janne Huhtala, Chief Executive
Officer, and Mikko Karvinen, Chief Financial Officer, who will present the
financial and operational results followed by a Q&A session. The presentation
material will be available on the Nexstim website shortly before the
conference call begins.

The dial-in numbers for the conference call are:

Finland: +358 (0) 800112363
Sweden: +46 (0) 850336434
UK: +44 (0) 8006940257
US: +1 (1) 6315107498

Standard International: +44 (0) 1452 555566

The call ID number is 47933395

NEXSTIM PLC
Janne Huhtala, Chief Executive Officer

For further information please visit
www.nexstim.comor contact:

Nexstim
+358 (0)40
8615046
Janne Huhtala, Chief Executive Officer janne.huhtala@nexstim.com

UB Securities Ltd
(Certified Adviser) +358 (0)9 2538 0246

Consilium Strategic Communications
+44 (0)20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Laura Thornton
nexstim@consilium-comms.com

About Nexstim Plc

Nexstim is a medical technology company aiming to improve rehabilitation for
stroke patients. Nexstim has pioneered its technology in brain diagnostics
with the Navigated Brain Stimulation (NBS) system as the first and only
FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS)
device for pre-surgical mapping of the motor and speech cortices. Based on
the same technology platform, the company has developed a device for stroke
therapy called Navigated Brain Therapy (NBT®). In H1 2014, Nexstim initiated
a two-year pivotal Phase III study at 12 sites in the US aiming to
demonstrate the effectiveness of NBT® and gain FDA clearance for
commercialisation in post-acute stroke therapy in the US. Nexstim's shares
are listed on Nasdaq First North Finland and Nasdaq First North Sweden. In H2
2015, the Company received a recommendation from the Data Safety Monitoring
Board (DSMB) to continue the Phase III stroke therapy NICHE trial without any
modifications. The first interim analysis on the NICHE (Navigated Inhibitory
rTMS to Contralesional Hemisphere) trial using NBT® was performed after 81
patients reached their primary safety outcome assessment, on track, at six
months post-treatment. For more information please visitwww.nexstim.com.

Publishing of Nexstim Plc 2015 Full Year Results
http://hugin.info/138152/R/1985084/727921.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nexstim Oyj via Globenewswire

HUG#1985084

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.